🏢 官网IRHRMYCodex · 实盘不做把握 9/10
北京时间·🕒 发布 20:05:00时区推断·⟳ 抓取 20:06:25·⚡ 决策 07-21 20:07:34 +1m09s·98.0 天前
Harmony Biosciences宣布将于2026年8月4日盘前披露二季度业绩
本次只是公司官网例行通知二季度业绩发布时间和电话会安排，未披露收入、利润、指引、产品或监管新增信息。
📄 原文HRMY↗ 原文
Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026
Skip to main navigation Media Corporate Careers Media Corporate Careers Release Details Harmony Biosciences To Report S…
不做 Harmony Biosciences（HRMY.US）
例行财报日程通知，不含业绩、指引或商业化新增信息，无法形成同向交易边界。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-21 · 扩散 low · price-in 风险 low ↗
关键理由
- 本次只是公司官网例行通知二季度业绩发布时间和电话会安排，未披露收入、利润、指引、产品或监管新增信息。
主要风险
- 真正可交易信息需等2026年8月4日盘前业绩和管理层指引披露后再重新判断。
原文全文
展开原文 · 1,981 字
Skip to main navigation
Media
Corporate
Careers
Media
Corporate
Careers
Release Details
Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026
July 21, 2026
PDF Version
PLYMOUTH MEETING, Pa. , July 21, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026 , before the open of the U.S . financial markets. Harmony will host a conference call and webcast on August 4, 2026 , at 8:30 a.m. ET to discuss the results.
To participate in the call, please dial 800-347-6865 (domestic) or 203-518-9757 (international or alternate), and reference passcode HRMYQ226. It is recommended that you dial in at least 10 minutes prior to the call.
The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/ .
About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa, we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com .
Harmony Biosciences Investor Contact:
Brennan Doyle
484-566-3685
bdoyle@harmonybiosciences.com
Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com
print page
email alerts
rss
contact ir
Media
Corporate
Careers
Media
Corporate
Careers
Release Details
Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026
July 21, 2026
PDF Version
PLYMOUTH MEETING, Pa. , July 21, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026 , before the open of the U.S . financial markets. Harmony will host a conference call and webcast on August 4, 2026 , at 8:30 a.m. ET to discuss the results.
To participate in the call, please dial 800-347-6865 (domestic) or 203-518-9757 (international or alternate), and reference passcode HRMYQ226. It is recommended that you dial in at least 10 minutes prior to the call.
The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/ .
About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa, we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com .
Harmony Biosciences Investor Contact:
Brennan Doyle
484-566-3685
bdoyle@harmonybiosciences.com
Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com
print page
email alerts
rss
contact ir
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。